Will INJ hold above $6.14 support amid seller dominance?
Injective (INJ) is trading at $6.62, down 7% on the day, with the move occurring below its key short-term moving averages but remaining above longer-term averages. The price is situated just under significant resistance levels, reflecting ongoing intraday pressure.
Highlights
- The Veyra mainnet upgrade for Injective won 99.51% staker approval, setting a milestone in network governance alignment.
- Injective protocol activity remains robust with $12.86 billion in Q3 2026 trading volume and 90,000 daily wallets, despite price pressure from recent broad digital asset selloffs.
- INJ trades below key short-term averages and momentum signals remain bearish, with an expected trading range of $6.14 to $7 over the next sessions.
Fed-driven risk reduction outweighs bullish governance milestone
The Veyra mainnet upgrade received 99.51% approval from INJ stakers, representing a major governance milestone and demonstrating strong community alignment for the planned network improvements, according to Phemex. While this upgrade reinforces Injective's long-term roadmap, recent market dynamics have overshadowed its immediate impact, as hawkish Federal Reserve meeting minutes have triggered broad digital asset selloffs and risk reduction, Finance Biggo reported. Fundamentals remain supported by active protocol usage, with Q3 2026 data from Coin Turk reflecting $12.86 billion in trading volume and 90,000 daily wallets, though price action has remained under broader selling pressure.
Oversold momentum as short-term resistance limits upside
Technically, INJ is trading below the H1 SMA-20 at $7.02 and H1 SMA-50 at $7.08, placing it under short- and medium-term resistance, while it remains above the D1 SMA-200 at $5.90, which provides longer-term structural support. The Ichimoku Kijun on the H1 chart is aligned near $6.97, marking the next immediate resistance to watch. Momentum indicators present a bearish bias with both MACD and ADX in negative territory, while all key oscillators display oversold conditions—RSI stands at 27.36, Stoch RSI at 3.35, and CCI at -187.21—signaling potential exhaustion of the current selling, but not a reversal. Bull/Bear Power at -0.28 further confirms seller dominance in intraday momentum.
Range-bound trade expected as breakout risks remain low
In the short term, INJ is expected to trade within a volatility band of $6.14 to $7, as the market digests current macro and technical signals. There is a 21% probability of a break to the upside, although the baseline expectation is continued consolidation within this range. A bullish scenario would only be triggered by a sustained move above the immediate resistance at $6.97, while renewed downside momentum may emerge if INJ falls and holds below support at $6.14.
Earlier, analysts noted that Injective was rebounding on ecosystem upgrades and regulatory developments, while technical signals pointed to persistent short-term resistance and downside pressure. The current update adds that despite strong community backing for the Veyra mainnet upgrade, ongoing macro headwinds and oversold conditions increase the importance of monitoring the $6.97 resistance as a trigger for any potential recovery.